酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析

林莉莉; 张妍; 刘志宏; 吴珏; 宋洪涛

doi:10.3969/j.issn.1006-0111.2019.03.016

酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析

doi: 10.3969/j.issn.1006-0111.2019.03.016

1.
联勤保障部队900医院药学科, 福建福州 350025
2.
联勤保障部队900医院肿瘤科, 福建福州 350025

基金项目: 福州总医院杰出青年培育项目（2016Q05）

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

1.
Department of Pharmacy, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China
2.
Department of Oncology, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

摘要: 目的通过相关回顾性病例收集研究，探究使用酪酸梭菌肠球菌三联活菌片是否具有提高晚期非小细胞肺癌（NSCLC）患者吉西他滨联合铂类（GP）化疗方案的疗效，减轻化疗带来的毒副作用。方法调取2014年1月至2018年7月在福州某三甲医院肿瘤科接受GP化疗方案治疗的晚期NSCLC患者的医疗记录，纳入78例患者的相关数据，采用SPSS 25.0软件进行数据统计分析。结果与对照组相比，使用酪酸梭菌肠球菌三联活菌片对患者的疾病控制率、无进展生存时间的影响具有显著性差异（P值分别为0.048、0.012），对疾病缓解率和不良反应风险的影响均无显著性差异（P>0.05）。结论在晚期NSCLC患者中，GP化疗方案治疗联合使用酪酸梭菌肠球菌三联活菌片可能提高患者的疗效。
- 酪酸梭菌肠球菌三联活菌片 /
- 肠道菌群 /
- 非小细胞肺癌 /
- 吉西他滨 /
- 铂类
Abstract: Objective To explore the effect of clostridium butyricum enterococcus triple viable tablet on the efficacy and adverse reactions of gemcitabine plus platinum(GP) regimen for the patients with advanced non-small cell lung cancer(NSCLC). Methods The records of 78 NSCLC patients who treated with GP regimen as first-line palliative chemotherapy were reviewed,and the related data were recorded.Statistical analyses were performed with SPSS 25.0. Results Compared with the control group,the probiotic preparation group showed a significant difference in disease control rate and progression-free survival (P value are 0.048 and 0.012 respectively),while there were no significant differences in objective response rate and the risk of adverse reaction events(P>0.05). Conclusion The clostridium butyricum enterococcus triple viable tablet might improve the efficacy of GP regimen as a first-line palliative chemotherapy for advanced NSCLC patients.
- clostridium butyricum enterococcus triple viable tablet /
- gut flora /
- NSCLC /
- gemcitabine /
- platinum

[1]	LEDERBERG J.Infectious history[J].Science,2000,288(5464):287-293.
[2]	GILLS R,POP M,DEBOY R T,et al. Metagenomic analysis of the human distal gut microbiome[J].Science,2006,312(5778):1355-1359.
[3]	O'HARAA M,SHANAHAN F.The gut flora as a forgotten organ[J].EMBO Rep,2006,7(7):688-693.
[4]	POPEJ L,TOMKOVICH S,YANG Y,et al. Microbiota as a mediator of cancer progression and therapy[J].Transl Res,2017,179:139-154.
[5]	FUHRMANB J,FEIGELSON H S,FLORES R,et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women[J].J Clin Endocrinol Metab,2014,99(12):4632-4640.
[6]	PRAGMANA A,KIM H B,REILLY C S,et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease[J].PLoS One,2012,7(10):e47305.
[7]	SCHWABER F,JOBIN C.The microbiome and cancer[J].Nat Rev Cancer,2013,13(11):800-812.
[8]	ZACKULARJ P,BAXTER N T,IVERSON K D,et al. The gut microbiome modulates colon tumorigenesis[J].mBio,2013,4(6):e613-e692.
[9]	ⅡDA N,DZUTSEV A,STEWARTC A,et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J].Science,2013,342(6161):967-970.
[10]	PEREZ-CHANONA E,TRINCHIERI G.The role of microbiota in cancer therapy[J].Curr Opin Immunol,2016,39:75-81.
[11]	VIAUD S,SACCHERI F,MIGNOT G,et al. Theintestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J].Science,2013,342(6161):971-976.[LinkOut]
[12]	ZITVOGEL L,GALLUZZI L,VIAUD S,et al. Cancer and the gut microbiota:an unexpected link[J].SciTransl Med,2015,7(271):271ps1.
[13]	CRONIN K A,LAKE A J,SCOTT S,et al. Annual report to the Nation on the status of cancer,part I:national cancer statistics[J].Cancer,2018,124(13):2785-2800.
[14]	YE T,PAN Y,WANG R,et al. Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old[J].J Thorac Dis,2014,6(10):1396-1402.
[15]	SCHILLER J H,HARRINGTON D,BELANI C P,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
[16]	VANDEVOORDE J,BALZARINI J,LIEKENS S.An emerging understanding of the Janus face of the human microbiome:enhancement versus impairment of cancer therapy[J].J Antimicrob Chemother,2014,69(10):2878-2880.
[17]	GELLERL T,BARZILY-ROKNI M,DANINO T,et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].Science,2017,357(6356):1156-1160.
[18]	GUI Q F,LU H F,ZHANG C X,et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model[J].Genet Mol Res,2015,14(2):5642-5651.
[19]	PALA V,SIERI S,BERRINO F,et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort[J].Int J Cancer,2011,129(11):2712-2719.
[20]	许春进,韩敏,徐峰,等.化疗药物对胃癌患者肠道菌群谱的影响及益生菌干预作用的临床研究[J].中华消化病与影像杂志(电子版),2016,6(4):154-159.
[21]	STEIN A,VOIGT W,JORDAN K.Chemotherapy-induced diarrhea:pathophysiology,frequency and guideline-based management[J].Ther Adv Med Oncol,2010,2(1):51-63.
[22]	陈晓慧.肺癌患者铂类药物化疗前后肠道菌群变化的相关研究[D].大连:大连医科大学,2016.
[23]	刘远预.含铂双药化疗对非小细胞肺癌患者肠道菌群的影响[D].大连:大连医科大学,2017.
[24]	孙曦.胃癌XELOX、肺癌GP化疗对肠道微生物的影响及口服地衣芽孢杆菌干预的研究[D].北京:中国人民解放军医学院,2016.
[25]	THERASSE P,ARBUCK S,EISENHAUER EA,et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
[26]	HUANG Y K,YANG W,LIU H,et al. Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria,Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia[J].Exp Biol Med (Maywood),2012,237(3):305-311.
[27]	STRINGERA M,GIBSON R J,LOGAN R M,et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis[J].Exp Biol Med (Maywood),2009,234(4):430-441.
[28]	LINX B,DIELEMAN L A,KETABI A,et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats[J].PLoS One,2012,7(7):e39764.
[29]	HEMARAJATA P,VERSALOVIC J.Effects of probiotics on gut microbiota:mechanisms of intestinal immunomodulation and neuromodulation[J].Therap Adv Gastroenterol,2013,6(1):39-51.
[30]	朱亮,虞秋国,乔鹏,等.地衣芽孢杆菌活菌胶囊对不能手术非小细胞肺癌GP化疗致肠道菌落失衡的影响[J].湖南师范大学学报(医学版),2018,15(3):85-87.
[31]	O'FLAHERTY S,SAULNIER D,POT B,et al. How can probiotics and prebiotics impact mucosal immunity?[J].Gut Microbes,2010,1(5):293-300.
[32]	HASSAN H,ROMPOLA M,GLASERA W,et al. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer[J].Support Care Cancer,2018,26(8):2503-2509.
[33]	REDMANM G,WARD E J,PHILLIPS R S.The efficacy and safety of probiotics in people with cancer:a systematic review[J].Ann Oncol,2014,25(10):1919-1929.

[1]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[2]	姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量. 巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
[3]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[4]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[5]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
[6]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[7]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[8]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[9]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[10]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 1-5. doi: 10.12206/j.issn.2097-2024.202405009
[11]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
[12]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[13]	黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉. 耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
[14]	史生辉, 石飞, 雷琼, 王亚峰, 吴雪花. 青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
[15]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[16]	尹小娟, 台力丽, 肖俊峰, 季波. 铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
[17]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[18]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[19]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[20]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023

点击查看大图

计量

文章访问数: 3593
HTML全文浏览量: 513
PDF下载量: 399
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析

doi: 10.3969/j.issn.1006-0111.2019.03.016

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

计量

酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析

doi: 10.3969/j.issn.1006-0111.2019.03.016

1. 联勤保障部队900医院药学科, 福建福州 350025

2. 联勤保障部队900医院肿瘤科, 福建福州 350025

English Abstract

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

1. Department of Pharmacy, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

2. Department of Oncology, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

全文HTML

目录

留言板

酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析

doi: 10.3969/j.issn.1006-0111.2019.03.016

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

计量

出版历程

酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析

doi: 10.3969/j.issn.1006-0111.2019.03.016

1. 联勤保障部队900医院 药学科, 福建 福州 350025 2. 联勤保障部队900医院 肿瘤科, 福建 福州 350025

English Abstract

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

1. Department of Pharmacy, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China 2. Department of Oncology, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

全文HTML

目录

1. 联勤保障部队900医院药学科, 福建福州 350025

2. 联勤保障部队900医院肿瘤科, 福建福州 350025

1. Department of Pharmacy, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

2. Department of Oncology, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China